Crohn’s Disease Market Is Booming With Eli Lilly and Co. (US), GlaxoSmithKline plc (UK), Janssen Biotech, Inc. (US), Johnson & Johnson
Global Crohn’s Disease Market By Procedures (Colonoscopy, Flexible Sigmoidoscopy, Computerized Tomography (CT), Magnetic Resonance Imaging (MRI), Capsule Endoscopy, Double-Balloon Endoscopy, Small Bowel Imaging), Therapeutic type {Non-surgical(Antibiotics, Anti-Diarrheal, Immune System Suppressors, Pain Relievers, Anti-Inflammatory Drugs), Surgical}, Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends & Forecast to 2026 Global Crohn’s Disease Market is expected to rise gradually to an estimated value of USD 13.52 billion by 2026, registering a CAGR of 4.1% in the forecast period of 2019-2026 with the annual sales of USD 9.8 billion in the year 2018. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients.
Request Sample of Global Crohn’s Disease Market Report 2019 @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-crohns-disease-market
Few of the major competitors currently working in the Crohn’s disease market are AbbVie Inc. (US), Allergan, Inc. (US), Bayer AG (Germany), Bristol-Myers Squibb (US), Boehringer Ingelheim GmbH (Germany), F. Hoffmann-La Roche (Switzerland), Eli Lilly and Co. (US), GlaxoSmithKline plc (UK), Janssen Biotech, Inc. (US), Johnson & Johnson (US), Novartis International AG (Switzerland), Pfizer Inc. (US), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), UCB S.A. (Belgium), Ferring B.V. (Switzerland), Tillotts Pharma AG (Switzerland) and few among others.
Market Definition:
Crohn’s Disease is also called as inflammatory bowel disease (IBD), as it causes inflammation of the gastro-intestinal tract resulting into abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Crohn’s disease is a rare disease, caused by a combination of factors involving genetics, the environment, and an overactive immune system.
According to the CDC, 3 million people in US and are suffering from Crohn’s Disease in 2015. Almost more than half of these cases could have been avoided with the availability of proper medical equipment and devices for healthcare procedures. This significant number is expected to act as a driver to the market growth.
Market Drivers
- High prevalence rate of the disease will drive the market.
- Prompt diagnosis of the disease and individual treatment of each symptom of the IBD can help in the growth of the market.
Market Restraints
- Lack of awareness about the available treatment options among the population that belongs to middle and low-income economies can hinder the market growth.
- Biologics going off-patent can increase the biosimilar competition that can affect the growth of the market.
Segmentation: Global Crohn’s Disease Market
By Procedures
- Colonoscopy
- Flexible Sigmoidoscopy
- Computerized Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Capsule Endoscopy
- Double-Balloon Endoscopy
- Small Bowel Imaging
By Therapeutic Type
- Non-surgical
- Antibiotics
- Anti-Diarrheal
- Immune System Suppressors
- Pain Relievers
- Anti-Inflammatory Drugs
- Surgical
By Geography
- North America
- South America
- Europe
- Asia-Pacific
- Middle East & Africa
Enquire for customization in Report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-crohns-disease-market
Key Developments in the Market:
- On 19th October, 2018, global pharmaceutical company, Mylan N.V. announced the commercial launch of Hulio™, a biosimilar to AbbVie’s Humira® (adalimumab), across major markets in Europe. The product is approved by EU for all adalimumab indications and after the patent expiry it has the potential to capture Humira’s market
- On 13th December 2017, Pfizer Inc. announced that the US-FDA has approved IXIFI™, a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade® (infliximab)* and it has the potential to capture the market shares of Remicade as the patent has expired.
- In April 2016, the U.S. Food and Drug Administration (FDA) approved Inflectra (Celtrion, Inc.), a biosimilar to Remicade (Janssen Biotech, Inc.) for patients suffering from Crohn’s disease. This approval will provide patients some other alternatives and help in the growth of the Crohn’s disease market.
Competitive Analysis:
Global Crohn’s disease market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Crohn’s disease market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Reasons to Purchase this Report
- Current and future of global Crohn’s disease market outlook in the developed and emerging markets
- The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
- Regions/Countries that are expected to witness the fastest growth rates during the forecast period
- The latest developments, market shares, and strategies that are employed by the major market players
Customization of the Report:
- All segmentation provided above in this report is represented at country level
- All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)
Table of Contents:
- Introduction
- Market Segmentation
- Market Overview
- Executive Summary
- Premium Insights
- Global, By Component
- Product Type
- Delivery
- Industry Type
- Geography
10.1. Overview
10.2. North America
10.3. Europe
10.4. Asia-Pacific
10.5. South America
10.6. Middle East & Africa
- Company Landscape
- Company Profiles
- Related Reports
Request For TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-crohns-disease-market
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email: [email protected]
